Cargando…
Radiotherapy for nonagenarians: the value of biological versus chronological age
BACKGROUND: The number of nonagenarian cancer patients (≥ 90 years) is continuously increasing, and radiotherapy is performed in a relevant proportion of patients, as surgery and chemotherapy are often not feasible for these patients. However, the evidence regarding the feasibility and treatment out...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236131/ https://www.ncbi.nlm.nih.gov/pubmed/32430009 http://dx.doi.org/10.1186/s13014-020-01563-x |
_version_ | 1783536099165995008 |
---|---|
author | Sprave, Tanja Rühle, Alexander Stoian, Raluca Weber, Alina Zamboglou, Constantinos Nieder, Carsten Grosu, Anca-Ligia Nicolay, Nils H. |
author_facet | Sprave, Tanja Rühle, Alexander Stoian, Raluca Weber, Alina Zamboglou, Constantinos Nieder, Carsten Grosu, Anca-Ligia Nicolay, Nils H. |
author_sort | Sprave, Tanja |
collection | PubMed |
description | BACKGROUND: The number of nonagenarian cancer patients (≥ 90 years) is continuously increasing, and radiotherapy is performed in a relevant proportion of patients, as surgery and chemotherapy are often not feasible for these patients. However, the evidence regarding the feasibility and treatment outcomes after radiotherapy for this patient group is very limited. METHODS: All nonagenarian patients receiving (chemo) radiotherapy between 2009 and 2019 at the University of Freiburg - Medical Center were analyzed for patterns of care, overall survival (OS) and therapy-associated toxicities according to the Common Terminology Criteria for Adverse Events. Uni- and multivariate Cox regression analyses were conducted to assess the influence of patient- and treatment-related factors on patient outcomes. RESULTS: One hundred nineteen patients with a total of 137 irradiated lesions were included in this analysis. After a median follow-up of 27 months, median OS was 10 months with a 3-year OS amounting to 11.1%. Univariate analyses demonstrated that a reduced performance status (HR = 1.56, 95% CI 1.00–2.45, p < 0.05), a higher burden of comorbidities (HR = 2.00, 95% CI 1.00–4.10, p < 0.05) and higher UICC tumor stages (HR = 2.21, 95% CI 1.14–4.26, p < 0.05) were associated with impaired survival rates. Split-course treatments (HR = 2.05, 95% CI 1.07–3.94, p < 0.05), non-completion of radiotherapy (HR = 7.17, 95% CI 3.88–13.26, p < 0.001) and palliative treatments (HR = 2.84, 95% CI 1.68–4.81, p < 0.05) were found to result in significantly reduced OS. In the multivariate analysis, split-course concepts (HR = 2.21, 95% CI 1.10–4.37, p < 0.05) and palliative treatments (HR = 3.19, 95% CI 1.77–5.75, p < 0.001) significantly deteriorated outcomes, while impaired ECOG status (HR = 1.49, 95% CI 0.91–2.43, p = 0.11) did not. The vast majority of patients reported either no (n = 40; 33.6%) or grade 1–2 acute toxicities (n = 66; 55.5%), and only very few higher-grade toxicities were observed in our study. CONCLUSION: Radiotherapy for nonagenarian patients is generally feasible and associated with a low toxicity profile. Given the relatively poor OS rates and the importance of the quality of life for this patient group, individualized treatment regimens including hypofractionation concepts should be considered. |
format | Online Article Text |
id | pubmed-7236131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-72361312020-05-27 Radiotherapy for nonagenarians: the value of biological versus chronological age Sprave, Tanja Rühle, Alexander Stoian, Raluca Weber, Alina Zamboglou, Constantinos Nieder, Carsten Grosu, Anca-Ligia Nicolay, Nils H. Radiat Oncol Research BACKGROUND: The number of nonagenarian cancer patients (≥ 90 years) is continuously increasing, and radiotherapy is performed in a relevant proportion of patients, as surgery and chemotherapy are often not feasible for these patients. However, the evidence regarding the feasibility and treatment outcomes after radiotherapy for this patient group is very limited. METHODS: All nonagenarian patients receiving (chemo) radiotherapy between 2009 and 2019 at the University of Freiburg - Medical Center were analyzed for patterns of care, overall survival (OS) and therapy-associated toxicities according to the Common Terminology Criteria for Adverse Events. Uni- and multivariate Cox regression analyses were conducted to assess the influence of patient- and treatment-related factors on patient outcomes. RESULTS: One hundred nineteen patients with a total of 137 irradiated lesions were included in this analysis. After a median follow-up of 27 months, median OS was 10 months with a 3-year OS amounting to 11.1%. Univariate analyses demonstrated that a reduced performance status (HR = 1.56, 95% CI 1.00–2.45, p < 0.05), a higher burden of comorbidities (HR = 2.00, 95% CI 1.00–4.10, p < 0.05) and higher UICC tumor stages (HR = 2.21, 95% CI 1.14–4.26, p < 0.05) were associated with impaired survival rates. Split-course treatments (HR = 2.05, 95% CI 1.07–3.94, p < 0.05), non-completion of radiotherapy (HR = 7.17, 95% CI 3.88–13.26, p < 0.001) and palliative treatments (HR = 2.84, 95% CI 1.68–4.81, p < 0.05) were found to result in significantly reduced OS. In the multivariate analysis, split-course concepts (HR = 2.21, 95% CI 1.10–4.37, p < 0.05) and palliative treatments (HR = 3.19, 95% CI 1.77–5.75, p < 0.001) significantly deteriorated outcomes, while impaired ECOG status (HR = 1.49, 95% CI 0.91–2.43, p = 0.11) did not. The vast majority of patients reported either no (n = 40; 33.6%) or grade 1–2 acute toxicities (n = 66; 55.5%), and only very few higher-grade toxicities were observed in our study. CONCLUSION: Radiotherapy for nonagenarian patients is generally feasible and associated with a low toxicity profile. Given the relatively poor OS rates and the importance of the quality of life for this patient group, individualized treatment regimens including hypofractionation concepts should be considered. BioMed Central 2020-05-19 /pmc/articles/PMC7236131/ /pubmed/32430009 http://dx.doi.org/10.1186/s13014-020-01563-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Sprave, Tanja Rühle, Alexander Stoian, Raluca Weber, Alina Zamboglou, Constantinos Nieder, Carsten Grosu, Anca-Ligia Nicolay, Nils H. Radiotherapy for nonagenarians: the value of biological versus chronological age |
title | Radiotherapy for nonagenarians: the value of biological versus chronological age |
title_full | Radiotherapy for nonagenarians: the value of biological versus chronological age |
title_fullStr | Radiotherapy for nonagenarians: the value of biological versus chronological age |
title_full_unstemmed | Radiotherapy for nonagenarians: the value of biological versus chronological age |
title_short | Radiotherapy for nonagenarians: the value of biological versus chronological age |
title_sort | radiotherapy for nonagenarians: the value of biological versus chronological age |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236131/ https://www.ncbi.nlm.nih.gov/pubmed/32430009 http://dx.doi.org/10.1186/s13014-020-01563-x |
work_keys_str_mv | AT spravetanja radiotherapyfornonagenariansthevalueofbiologicalversuschronologicalage AT ruhlealexander radiotherapyfornonagenariansthevalueofbiologicalversuschronologicalage AT stoianraluca radiotherapyfornonagenariansthevalueofbiologicalversuschronologicalage AT weberalina radiotherapyfornonagenariansthevalueofbiologicalversuschronologicalage AT zamboglouconstantinos radiotherapyfornonagenariansthevalueofbiologicalversuschronologicalage AT niedercarsten radiotherapyfornonagenariansthevalueofbiologicalversuschronologicalage AT grosuancaligia radiotherapyfornonagenariansthevalueofbiologicalversuschronologicalage AT nicolaynilsh radiotherapyfornonagenariansthevalueofbiologicalversuschronologicalage |